Inflammasome Therapeutics Announces Promising Phase 2 Results for K8 in Geographic Atrophy
Inflammasome Therapeutics has reported positive results from a Phase 2 clinical trial of its investigational drug K8 for the treatment of geographic atrophy (GA), a severe form of dry age-related macular degeneration. The trial demonstrated that K8 significantly slowed the progression of GA and improved visual acuity over a six-month period. The study involved 30 participants with bilateral GA, and the drug was administered as a bioerodible sustained-release intravitreal implant. The 0.7 mg dose cohort showed a 54% reduction in the mean rate of GA growth compared to the control group, and a 4.0-letter mean advantage in best-corrected visual acuity was observed. These results were presented at the American Society of Retina Specialists Annual Meeting in Montreal. 
